Michael B Fisher

Summary

Affiliation: Boehringer Ingelheim

Publications

  1. ncbi In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance
    Timothy J Strelevitz
    Pfizer Inc, PGRD, Pharmacokinetics, Dynamics, and Metabolism, Eastern Point Road, Groton, CT 06340, USA
    J Pharm Sci 95:1334-41. 2006
  2. ncbi Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
    Paul S Changelian
    Immunology Group, Department of Antibacterials and Immunology, Pfizer Global Researchand Development, Groton, CT 06340, USA
    Science 302:875-8. 2003
  3. ncbi Altered AZT (3'-azido-3'-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment
    Juntyma J Engtrakul
    Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Groton, CT 06340, USA
    Drug Metab Dispos 33:1621-7. 2005
  4. ncbi A streamlined method to predict hepatic clearance using human liver microsomes in the presence of human plasma
    Sara M Skaggs
    Pfizer Global Research and Development, Pharmacokinetics, Dynamics, and Metabolism Pfizer, Inc. Groton, CT 06340, USA
    J Pharmacol Toxicol Methods 53:284-90. 2006
  5. ncbi The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism
    Michael B Fisher
    Boehringer Ingelheim Pharmaceuticals Inc, 900 Ridgebury Road, Ridgefield, CT 06877, USA
    Curr Opin Drug Discov Devel 9:101-9. 2006
  6. ncbi Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems
    Daniel R Albaugh
    Boehringer Ingelheim Pharmaceuticals Inc, Medicinal Chemistry Drug Metabolism and Pharmacokinetics, 175 Briar Ridge Road, R and D 10574, Ridgefield, CT 06877, USA
    Drug Metab Dispos 40:1336-44. 2012
  7. ncbi Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes
    J Matthew Hutzler
    Boehringer Ingelheim Pharmaceuticals Inc, Translational Research Drug Metabolism and Pharmacokinetics, 175 Briar Ridge Road, R and D 10578, Ridgefield, CT 06877, USA
    Drug Metab Dispos 40:267-75. 2012
  8. ncbi The role of the intestine in drug metabolism and pharmacokinetics: an industry perspective
    Michael B Fisher
    Cara Therapeutics, Tarrytown, NY 10591, USA
    Curr Drug Metab 8:694-9. 2007
  9. ncbi Recent advances in high throughput screening for ADME properties
    Timothy J Carlson
    Amgen Inc, 1120 Veterans Boulevard, South San Francisco, CA 94080, USA
    Comb Chem High Throughput Screen 11:258-64. 2008

Collaborators

  • D C Borie
  • J Matthew Hutzler
  • Daniel R Albaugh
  • Michael J Munchhof
  • Timothy J Strelevitz
  • Robert S Foti
  • Timothy J Carlson
  • Sara M Skaggs
  • Juntyma J Engtrakul
  • Paul S Changelian
  • Eileen A Elliott
  • Brett M Lillie
  • Deborah Finco-Kent
  • Ming-Sing Si
  • Chakrapani Subramanyam
  • Shelley G Des Etages
  • Erika R Koslov
  • John L Doty
  • Chang Shang-Poa
  • Lisa S Hayes
  • Ricardo Paniagua
  • Elizabeth M Kudlacz
  • David A Whipple
  • Mark E Flanagan
  • Jianmin Sun
  • Chunyan Su
  • Perry S Sawyer
  • Anderson S Gaweco
  • William H Brissette
  • Maryrose J Conklyn
  • Kelly S Magnuson
  • Yong jie Zhou
  • Matthew F Brown
  • Gretchen E Beckius
  • Bari Holm
  • Sandra P McCurdy
  • Douglas A Fisher
  • William H Martin
  • Bruce Reitz
  • Anthony J Milici
  • Chan R Beals
  • Jeffrey M Casavant
  • Bonnie J Rizzuti
  • Douglas J Ball
  • Michael Hines
  • Linda F Nelms
  • Todd A Blumenkopf
  • Yong-Jie Zhou
  • Randall E Morris
  • Deanna L Baker
  • Thasia G Woodworth
  • Bret D Perry
  • James F Smith
  • Kimberly S Johnson
  • Panayiotis Zagouras
  • Mary J Saltarelli
  • Ming Sing Si
  • Craig R Kent
  • Thomas T Kawabata
  • Bruce H Littman
  • James D Moyer
  • John Higgins
  • Holly A Magna
  • Michael Larson
  • JOHN J O'SHEA
  • Kwansik Yoon

Detail Information

Publications9

  1. ncbi In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance
    Timothy J Strelevitz
    Pfizer Inc, PGRD, Pharmacokinetics, Dynamics, and Metabolism, Eastern Point Road, Groton, CT 06340, USA
    J Pharm Sci 95:1334-41. 2006
    ..This method should have utility in drug discovery for the identification of factors limiting oral bioavailability...
  2. ncbi Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
    Paul S Changelian
    Immunology Group, Department of Antibacterials and Immunology, Pfizer Global Researchand Development, Groton, CT 06340, USA
    Science 302:875-8. 2003
    ..On the basis of these preclinical results, we believe JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation and in other clinical settings...
  3. ncbi Altered AZT (3'-azido-3'-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment
    Juntyma J Engtrakul
    Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Groton, CT 06340, USA
    Drug Metab Dispos 33:1621-7. 2005
    ....
  4. ncbi A streamlined method to predict hepatic clearance using human liver microsomes in the presence of human plasma
    Sara M Skaggs
    Pfizer Global Research and Development, Pharmacokinetics, Dynamics, and Metabolism Pfizer, Inc. Groton, CT 06340, USA
    J Pharmacol Toxicol Methods 53:284-90. 2006
    ....
  5. ncbi The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism
    Michael B Fisher
    Boehringer Ingelheim Pharmaceuticals Inc, 900 Ridgebury Road, Ridgefield, CT 06877, USA
    Curr Opin Drug Discov Devel 9:101-9. 2006
    ..The concepts and evidence behind this phenomenon as it relates to complexities in blocking metabolic clearance are presented herein...
  6. ncbi Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems
    Daniel R Albaugh
    Boehringer Ingelheim Pharmaceuticals Inc, Medicinal Chemistry Drug Metabolism and Pharmacokinetics, 175 Briar Ridge Road, R and D 10574, Ridgefield, CT 06877, USA
    Drug Metab Dispos 40:1336-44. 2012
    ..Overall, results from these studies suggest that in vitro inactivation parameters generated from plated cell systems may be a practical approach for identifying time-dependent inhibitors and for estimating the magnitude of clinical DDIs...
  7. ncbi Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes
    J Matthew Hutzler
    Boehringer Ingelheim Pharmaceuticals Inc, Translational Research Drug Metabolism and Pharmacokinetics, 175 Briar Ridge Road, R and D 10578, Ridgefield, CT 06877, USA
    Drug Metab Dispos 40:267-75. 2012
    ..These data taken together suggest that the use of cryopreserved hepatocytes may be a practical approach for assessing AO-mediated metabolism in discovery and potentially useful for predicting hepatic clearance of AO substrates...
  8. ncbi The role of the intestine in drug metabolism and pharmacokinetics: an industry perspective
    Michael B Fisher
    Cara Therapeutics, Tarrytown, NY 10591, USA
    Curr Drug Metab 8:694-9. 2007
    ..The opportunity exists to increase the examination of intestinal metabolism of drugs and drug candidates in industry...
  9. ncbi Recent advances in high throughput screening for ADME properties
    Timothy J Carlson
    Amgen Inc, 1120 Veterans Boulevard, South San Francisco, CA 94080, USA
    Comb Chem High Throughput Screen 11:258-64. 2008
    ..Future advances will further improve the ability to make decisions on molecules earlier in drug discovery...